June 27, 2025

FDA Approves Pembrolizumab for HER2-Positive Gastric or GEJ Cancer Expressing PD-L1

Traditional approval was granted to the PD-L1 inhibitor with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresecta...

The ASCO Post

June 27, 2025

Novel Antibody-Drug Conjugate in Advanced Gastric/Gastroesophageal Junction Cancer

In a Chinese phase I trial (KYM901) reported in The Lancet Oncology, Ruan et al reported on CMG901—a first-in-class claudin 18.2–targeting antibody-drug conjugate—in patients with advanced gastric or ...

The ASCO Post

June 27, 2025

Bacterial Leakage Across Gastric Lining Could Signify Cancer Risk

Researchers uncovered insights into the potential role of bacteria in the development of gastric cancer.

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

December 09, 2024

Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit

Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data prese...

The ASCO Post

May 09, 2024

Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer

Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric o...

The ASCO Post

May 03, 2023

First-Line Zolbetuximab Plus mFOLFOX6 in CLDN18.2-Positive, HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

As reported in The Lancet by Kohei Shitara, MD, and colleagues, the phase III SPOTLIGHT trial has shown significantly prolonged progression-free and overall survival with the addition of the anti–clau...

The ASCO Post

June 13, 2023

Study Illuminates Potential Marked Disparities in Federal Cancer Research Funding

Investigators have found that federal cancer research funding tends to be allocated more heavily toward cancers that occur more often in non-Hispanic White patients than those that occur more frequent...

The ASCO Post

May 13, 2024

Oral Rinse Could Provide Early Screening for Gastric Cancer

A simple oral rinse may lead to early detection of gastric cancer, according to new findings presented at Digestive Disease Week (DDW) 2024.

The ASCO Post